5 Einträge gefunden

1. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis

   1. Gordon, K B
   2. Lebwohl, M
   3. Papp, K A
   4. Bachelez, H
   5. Wu, J J
   6. Langley, R G
   7. Blauvelt, A

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab

   1. Kimball, A B
   2. Kerbusch, T
   3. van Aarle, F
   4. Kulkarni, P
   5. Li, Q
   6. Blauvelt, A
   7. Papp, K A

   2020 - Forschungsinformationssystem des UKE
3. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies

   1. Kimball, A B
   2. Papp, K A
   3. Reich, K
   4. Gooderham, M
   5. Li, Q
   6. Cichanowitz, N
   7. La Rosa, C

   2020 - Forschungsinformationssystem des UKE
4. Continuous Dosing Versus Interrupted Therapy with Ixekizumab: An Integrated Analysis of Two Phase 3 Trials in Psoriasis

   1. Blauvelt, Andrew
   2. Papp, K A
   3. Sofen, H L
   4. Augustin, M
   5. Yosipovitch, Gil
   6. Katoh, N
   7. Mrowietz, U

   2017 - Forschungsinformationssystem des UKE
5. Drug Survival of Biologic Therapy in a Large, Disease-based Registry of Patients with Psoriasis: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

   1. Menter, A
   2. Papp, K A
   3. Gooderham, M
   4. Pariser, D M
   5. Augustin, M
   6. Kerdel, F A
   7. Fakharzadeh, S

   2016 - Forschungsinformationssystem des UKE